CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER).
CLINIMIX 4.25/5 is a parenteral nutrition solution providing amino acids and dextrose for protein synthesis and energy metabolism. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for cellular energy production via glycolysis and oxidative phosphorylation.
| Metabolism | Amino acids are metabolized via deamination, transamination, and urea cycle pathways. Dextrose is metabolized via glycolysis and the Krebs cycle. |
| Excretion | The components (amino acids and dextrose) are metabolized; excess nitrogen is excreted renally as urea (about 85-90%), with minor fecal loss (<5%). Dextrose is fully metabolized to CO2 and water, with negligible renal excretion. |
| Half-life | Amino acids: variable, with terminal half-life of individual amino acids ranging from 0.5 to 3 hours. Clinical context: continuous infusion maintains steady-state levels; used for nutritional support. |
| Protein binding | Amino acids: minimal to negligible binding (<10%), primarily to albumin for certain hydrophobic amino acids like tryptophan (up to 70% bound). Dextrose: not protein-bound. |
| Volume of Distribution | Amino acids: Vd ~0.3-0.4 L/kg, approximating total body water; dextrose initial Vd ~0.2 L/kg (extracellular), equilibrates to total body water. Clinical meaning: distribution to lean body mass and extracellular fluid. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within minutes) as infusion begins; nitrogen balance improvement detectable within 24 hours. |
| Duration of Action | Intravenous: duration of action persists as long as infusion continues (hours to days, depending on rate). Clinical note: effects on nitrogen balance, blood glucose, and amino acid levels reverse shortly after infusion cessation. |
IV, dosage individualized based on protein and energy requirements. Typical adult dose: 1.5 g/kg/day of amino acids (4.25% solution) as part of total parenteral nutrition, infused at a rate not exceeding 0.1 g/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 30 mL/min/1.73 m²: reduce amino acid dose to 0.8-1.0 g/kg/day. For GFR 30-60: 1.0-1.5 g/kg/day. Monitor for azotemia. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce amino acids to 0.8-1.2 g/kg/day. Class C: use with caution; may require 0.5-0.8 g/kg/day and branched-chain amino acid-enriched formulations. |
| Pediatric use | Neonates and infants: start at 1.5-2 g/kg/day amino acids, increase to 2.5-3.5 g/kg/day as tolerated. Children: 1.5-2.5 g/kg/day. Administer at 0.1-0.15 g/kg/hour. |
| Geriatric use | Initiate at lower end of dosing range (1.0-1.2 g/kg/day amino acids) due to reduced renal and hepatic function. Monitor fluid and electrolyte balance closely; adjust for comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Excretion of components into breast milk is expected; M/P ratio not established. Use caution; monitor infant for adverse effects. |
| Teratogenic Risk | No evidence of teratogenicity from amino acid or dextrose components; no specific trimester risks identified. Use only if clearly needed due to maternal benefit. |
| Fetal Monitoring |
■ FDA Black Box Warning
None for this specific formulation; however, parenteral nutrition solutions carry risks of infection, metabolic complications, and fluid overload.
| Serious Effects |
["Known hypersensitivity to any component","Uncorrected metabolic disorders (e.g., phenylketonuria)","Severe electrolyte or acid-base imbalance","Anuria or acute renal failure","Hepatic coma"]
| Precautions | ["Risk of infection related to catheter use","Electrolyte imbalances","Hyperglycemia or hypoglycemia","Fluid overload","Liver function abnormalities","Refeeding syndrome in malnourished patients","Aluminum toxicity with prolonged use"] |
Loading safety data…
| Monitor maternal electrolytes, fluid balance, renal function, and blood glucose. Fetal monitoring as clinically indicated. |
| Fertility Effects | No known adverse effects on fertility from amino acids or dextrose at therapeutic doses. |